Onkologie/Oncology group is focused on clinical translation of novel imaging and therapy for cancer. Our aim is to translate molecular imaging and radionuclide therapy concepts to achieve improved outcomes in cancer patients.
Focus on theranostic
Major focus is the assessment of theranostic radioligands and radionuclides, i.e. molecules designed to deliver radioactive payloads into tumor lesions. Theranostic radioligands/radionuclides enable a combination of accurate detection and efficacious radionuclide therapy. Our research aims for substantial clinical improvement leading to guideline implementation.
Theranostic Radio Ligands bind to specific surface targets of cancer cells. Upon binding Radio Ligands undergo subsequent internalization and radioactive decay. Decay emissions are designed for tumor imaging and internal radiotherapy.
Clinical projects assess the impact of molecular imaging on tumor detection, clinical stage and outcome. Longitudinal cohort studies examine the efficacy and safety of radionuclide therapy. Projects are carried out in close collaboration with Oncology, Urology and other Clinical Partners.
Translational research builds onto our preclinical findings and explores new theranostic applications. Translational projects address among other topics a current NEED for the advancement of theranostic:
- N ovel cancer targets for radionuclide imaging and therapy
- E nhanced target expression
- E scalation of activity and radiation dose
- D rug combination therapy
Financial support is provided by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG), Mercator Research Center Ruhr (MERCUR), IFORES, Doktor Robert Pfleger-Stiftung, Wiedenfeld-Stiftung/Stiftung Krebsforschung Duisburg, Landeskrebsregister NRW, Winterseminar UKE, and SOFIE Bioscience.